Clik here to view.
海外投資家が注目するがん治療日本独自技術のANK免疫細胞療法に焦点：リンパ球バンク株式会社
東京 （ビジネスワイヤ） – がん免疫治療で先進的な取り組みをしている京都大学発のベンチャー企業、リンパ球バンク株式会社（本社：東京都千代田区、代表取締役：藤井真則）が、海外投資家から注目されています。 このSmart News Release（スマート・ニュース・リリース）にはマルチメディアのコンテンツが含まれています。リリース全文はこちらから：...
View ArticleClik here to view.
Clik here to view.
Kymab and EpimAb Biotherapeutics Announce Multi-Target, Bispecific Antibody...
CAMBRIDGE, United Kingdom & SHANGHAI Kymab, a leading human monoclonal antibody biopharmaceutical company, and EpimAb Biotherapeutics, an emerging biopharmaceutical company specializing in...
View ArticleClik here to view.
NCKU Alumni in Malaysia Run for Charity
TAINAN, Taiwan Secretariat Ackum, the alumni association of NCKU in Malaysia, hosted the ACKU Charity Run 2016, which highlighted the value of ethnicity-friendly, at the University of Malaya (UM) on...
View ArticleClik here to view.
Gynesonics Announces Early Completion of Enrollment in the SONATA FDA...
REDWOOD CITY, Calif. Gynesonics, a women’s healthcare company focused on the development of advanced incision-free solutions for treatment of benign uterine conditions, today announced the...
View ArticleClik here to view.
Takeda Showcases Continued Commitment in Hodgkin Lymphoma During 10th...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502) will present data on ADCETRIS® (brentuximab vedotin) in Hodgkin lymphoma at the 10th International Symposium on...
View ArticleClik here to view.
Astellas Reports First Half FY2016 Financial Results, Revises Fiscal Year...
TOKYO Astellas Pharma Inc. (TOKYO:4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced financial results for the first six months of fiscal year 2016 ending March 31, 2017...
View ArticleClik here to view.
Takeda Reports First Half FY2016 Results and Raises Full Year Profit Guidance
OSAKA, Japan Takeda Pharmaceutical Company Limited (TOKYO:4502): Strong first half results led by Growth Drivers Underlying Revenue grew +7.4%, led by a +15.3% increase of Takeda’s Growth...
View ArticleClik here to view.
2016年度上期（4‐9月期）の連結業績について当期利益およびEPSの年間予想、実質的なコア・アーニングスのマネジメントガイダンスを上方修正
大阪 （ビジネスワイヤ） — 武田薬品工業株式会社 （東証：4502）： タケダ成長ドライバーが力強い上期実績を牽引 売上収益の実質的な成長は、タケダ成長ドライバー（消化器系疾患領域、オンコロジー、中枢神経系疾患領域、新興国事業）の＋15.3％の伸長により、対前年同期＋7.4％を達成。財務ベースでは、為替影響（△8.6ポイント）や事業等の売却影響（△4.7ポイント）により対前年同期△5.9％...
View ArticleClik here to view.
武田公布2016财年上半年业绩并提高全年利润指引
日本大阪 (美国商业资讯)–武田药品工业株式会社(TOKYO:4502)： 强劲的上半年业绩得益于增长引擎 得益于武田增长引擎（胃肠药、肿瘤药、CNS和新兴市场）+15.3%的增长，基础营收增长+7.4%。 由于不利的汇率影响（-8.6个百分点）和剥离影响（-4.7个百分点），报告的营收下降5.9%。...
View ArticleClik here to view.
Takeda to Present Broad Range of Clinical Data During 58th American Society...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that it will present a total of 16 company-sponsored abstracts at the 58th American Society of...
View ArticleClik here to view.
Seattle Genetics and Takeda Complete Enrollment of Phase 3 ECHELON-2 Clinical...
BOTHELL, Wash. & CAMBRIDGE, Mass. Seattle Genetics, Inc. (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced completion of patient enrollment in the ECHELON-2...
View ArticleClik here to view.
Sosei Subsidiaries Heptares and Jitsubo to Develop Novel GPCR-Targeting...
TOKYO Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565) announces that its subsidiaries, Heptares Therapeutics (“Heptares”) and Jitsubo Co., Ltd. (“Jitsubo”), have entered into a...
View ArticleClik here to view.
Cell Culture Company (C3) Deal Targets Pancreatic Cancer
MINNEAPOLIS Cell Culture Company (C3), a biopharmaceutical developer and manufacturer, announced today it has entered into an agreement with a China-based joint venture to produce a clinical-grade...
View ArticleClik here to view.
UC San Francisco Professor Receives Honorary Doctorate from NCKU
TAINAN, Taiwan Dr. Zena Werb, professor and vice chair of the Department of Anatomy at University of California (UC), San Francisco, USA, received an honorary doctoral degree from National Cheng...
View ArticleClik here to view.
NINLARO™ (ixazomib) Receives Conditional Approval from the European...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Commission has granted conditional marketing authorization for NINLAROTM...
View ArticleClik here to view.
Sosei Subsidiaries Heptares to Acquire G7 Therapeutics to Extend Leadership...
TOKYO Sosei Group Corporation (“Sosei”; TOKYO Mothers Index: 4565) today announces that Heptares Therapeutics (“Heptares”), the wholly-owned subsidiary of Sosei, has signed a share purchase...
View ArticleClik here to view.
Minomic Announces Completion of Oversubscribed Capital Raising at AGM
SYDNEY Immuno-oncology company, Minomic International Ltd, announced the successful completion of its current funding round at its Annual General Meeting of Shareholders on Tuesday November 29. The...
View ArticleClik here to view.
Takeda and Seattle Genetics Report Positive Phase 3 ALCANZA Clinical Trial...
CAMBRIDGE, Mass. & OSAKA, Japan & BOTHELL, Wash. Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ALCANZA...
View ArticleClik here to view.
Solasia Pharma and Meiji Seika Pharma Announce License and Distribution...
TOKYO Solasia Pharma K.K. (Headquarters: Tokyo, Japan, President: Yoshihiro Arai, hereinafter “Solasia”) announced today that Solasia and Meiji Seika Pharma Co. Ltd., (Headquarters: Tokyo, Japan,...
View Article